Stoke Therapeutics, Inc.
zorevunersen
Dravet syndrome
Countdown
358days
FDA decision · ~ Jun 30, 2027 estimated
What's at stake
The FDA's approval decision on zorevunersen for Dravet syndrome is due ~ Jun 30, 2027. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that is anticipated to support the submission of a New Drug Application (an “NDA”) to the U.S. Food and Drug Administr”